Kailera Therapeutics is trading 4.7% up at $21.99 in pre-market. This positive movement follows the company's announcement on July 7, 2026, of positive topline data from two Phase 3 trials of its oral GLP-1 agonist, KAI-7535, for diabetes and metabolic outcomes. - While the initial market reaction to the data on July 7 saw the stock decline due to concerns over gastrointestinal side effects, today's rise may reflect a re-evaluation of the efficacy. - The Phase 3 results, originally announced by partner Hengrui Pharma, have shown promising efficacy for the KAI-7535/HRS-7535 candidate. - Kailera is also advancing a global Phase 2 obesity trial for the same candidate, which commenced in April 2026, strengthening its metabolic pipeline.